Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Prices $180M Public Stock Offering

NEW YORK – Veracyte said after the market closed Tuesday afternoon that it has priced a public offering of 6 million shares of its common stock at $30 per share. It expects gross proceeds of around $180 million.

Veracyte will use the net proceeds from the offering for working capital and other general corporate purposes. The firm may also use part of the proceeds to acquire or invest in complementary businesses, technologies, or other assets.

Goldman Sachs and SVB Leerink are joint lead book-running managers for the offering, while William Blair is a book-running manager and BTIG, Needham, and Lake Street Capital Markets are co-managers.

Veracyte has granted underwriters a 30-day stock option to purchase up to an additional 900,000 shares of its common stock at the public offering price. The offering is expected to close around Aug. 7, 2020, the firm said.

Veracyte's stock was down about 7 percent at $30.00 in Wednesday morning trading on the Nasdaq.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.